These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37853129)

  • 1. Bacteriophages suppress CRISPR-Cas immunity using RNA-based anti-CRISPRs.
    Camara-Wilpert S; Mayo-Muñoz D; Russel J; Fagerlund RD; Madsen JS; Fineran PC; Sørensen SJ; Pinilla-Redondo R
    Nature; 2023 Nov; 623(7987):601-607. PubMed ID: 37853129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical organizations and epistatic interactions of CRISPRs and cas clusters in genomes and their mobile genetic elements.
    Bernheim A; Bikard D; Touchon M; Rocha EPC
    Nucleic Acids Res; 2020 Jan; 48(2):748-760. PubMed ID: 31745554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type II anti-CRISPR proteins as a new tool for synthetic biology.
    Zhang Y; Marchisio MA
    RNA Biol; 2021 Aug; 18(8):1085-1098. PubMed ID: 32991234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meet the Anti-CRISPRs: Widespread Protein Inhibitors of CRISPR-Cas Systems.
    Hwang S; Maxwell KL
    CRISPR J; 2019 Feb; 2(1):23-30. PubMed ID: 31021234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems.
    Mohanraju P; Makarova KS; Zetsche B; Zhang F; Koonin EV; van der Oost J
    Science; 2016 Aug; 353(6299):aad5147. PubMed ID: 27493190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type II Anti-CRISPR Proteins.
    Hwang S; Maxwell KL
    J Mol Biol; 2023 Apr; 435(7):168041. PubMed ID: 36893938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse viral cas genes antagonize CRISPR immunity.
    Katz MA; Sawyer EM; Oriolt L; Kozlova A; Williams MC; Margolis SR; Johnson M; Bondy-Denomy J; Meeske AJ
    Nature; 2024 Oct; 634(8034):677-683. PubMed ID: 39232173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CRISPR-Cas systems by mobile genetic elements.
    Sontheimer EJ; Davidson AR
    Curr Opin Microbiol; 2017 Jun; 37():120-127. PubMed ID: 28668720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based functional mechanisms and biotechnology applications of anti-CRISPR proteins.
    Jia N; Patel DJ
    Nat Rev Mol Cell Biol; 2021 Aug; 22(8):563-579. PubMed ID: 34089013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phage-Encoded Anti-CRISPR Defenses.
    Stanley SY; Maxwell KL
    Annu Rev Genet; 2018 Nov; 52():445-464. PubMed ID: 30208287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Keeping crispr in check: diverse mechanisms of phage-encoded anti-crisprs.
    Trasanidou D; Gerós AS; Mohanraju P; Nieuwenweg AC; Nobrega FL; Staals RHJ
    FEMS Microbiol Lett; 2019 May; 366(9):. PubMed ID: 31077304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coevolution between bacterial CRISPR-Cas systems and their bacteriophages.
    Watson BNJ; Steens JA; Staals RHJ; Westra ER; van Houte S
    Cell Host Microbe; 2021 May; 29(5):715-725. PubMed ID: 33984274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobile Genetic Elements and Evolution of CRISPR-Cas Systems: All the Way There and Back.
    Koonin EV; Makarova KS
    Genome Biol Evol; 2017 Oct; 9(10):2812-2825. PubMed ID: 28985291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophages are associated with extensive CRISPR-Cas auto-immunity.
    Nobrega FL; Walinga H; Dutilh BE; Brouns SJJ
    Nucleic Acids Res; 2020 Dec; 48(21):12074-12084. PubMed ID: 33219687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species.
    Pawluk A; Staals RH; Taylor C; Watson BN; Saha S; Fineran PC; Maxwell KL; Davidson AR
    Nat Microbiol; 2016 Jun; 1(8):16085. PubMed ID: 27573108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CRISPRs go viral: The infection biology of CRISPR-Cas inhibitors.
    Li Y; Bondy-Denomy J
    Cell Host Microbe; 2021 May; 29(5):704-714. PubMed ID: 33444542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
    Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
    mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of temperate phages drives loss of type I CRISPR-Cas systems.
    Rollie C; Chevallereau A; Watson BNJ; Chyou TY; Fradet O; McLeod I; Fineran PC; Brown CM; Gandon S; Westra ER
    Nature; 2020 Feb; 578(7793):149-153. PubMed ID: 31969710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I-F CRISPR-Cas resistance against virulent phages results in abortive infection and provides population-level immunity.
    Watson BNJ; Vercoe RB; Salmond GPC; Westra ER; Staals RHJ; Fineran PC
    Nat Commun; 2019 Dec; 10(1):5526. PubMed ID: 31797922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disabling a Type I-E CRISPR-Cas Nuclease with a Bacteriophage-Encoded Anti-CRISPR Protein.
    Pawluk A; Shah M; Mejdani M; Calmettes C; Moraes TF; Davidson AR; Maxwell KL
    mBio; 2017 Dec; 8(6):. PubMed ID: 29233895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.